BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, November 1, at 5:00 p.m. ET (23:00 CET) to discuss third quarter 2007 financial results.

  U.S. / Canada Dial-in Number:  866.713.8307
  International Dial-in Number:  617.597.5307
  Participant Code: 48736710
  Replay Dial-in Number: 888.286.8010
  Replay International Dial-in Number: 617.801.6888
  Replay Code: 41531207

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, http://www.bmrn.com/. A replay of the call will be archived on the site for at least one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio is comprised of two approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, and Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation. Investigational product candidates include Kuvan(TM) (sapropterin dihydrochloride), a Phase 3 product candidate for the treatment of phenylketonuria (PKU), and 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease.

  Naglazyme(R) is a registered trademark of BioMarin Pharmaceutical Inc.

  Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

   Contacts:

   Investors                                   Media
   Eugenia Shen                                Susan Berg
   BioMarin Pharmaceutical Inc.                BioMarin Pharmaceutical Inc.
   (415) 506-6570                              (415) 506-6594

First Call Analyst:
FCMN Contact: sberg@bmrn.com

SOURCE: BioMarin Pharmaceutical Inc.